Nature Medicine: gene therapy for Duchenne muscular dystrophy
January 29, 2020. Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease in children. Researchers from the Technical University of Munich (TUM) and other institutions have developed a gene therapy that can provide permanent relief for patients with DMD.
The dystrophin protein is key to muscle tissue regeneration. People with Duchenne muscular dystrophy lack this essential protein due to gene mutations, so their muscle cells degenerate over time and are gradually replaced by connective tissue and adipose tissue. DMD mainly affects males because the key mutation site is located on the X chromosome.
Scientists at TUM have, for the first time, successfully repaired the mutated dystrophin gene in pigs by optimizing the Crispr-Cas9 gene editing technology. Professor Wolfgang Wurst, a geneticist at TUM and the Helmholtz Zentrum München, said: "These gene scissors are very effective and can correct the dystrophin gene." Compared with diseased animals that did not receive the treatment, the treated animals were less susceptible to cardiac arrhythmia and had an increased life expectancy.
Cardiologist Professor Christian Kupatt said: "Muscle and heart cells are long-lived cell structures. Throughout the entire life cycle from birth to death, half of all cardiomyocytes can still maintain function. As long as the cell is alive, its genome can be used for protein biosynthesis; once the cell is affected by treatment, it will remain in the corrected state. Therefore, if we change the genome of cardiomyocytes, a long-term effect will be achieved." Source: 生物谷. Information source: New gene correction therapy for Duchenne muscular dystrophy. Original source: A. Moretti, L. Fonteyne, F. Giesert, P. Hoppmann, A. B. Meier, T. Bozoglu, A. Baehr, C. M. Schneider, D. Sinnecker, K. Klett, T. Fröhlich, F. Abdel Rahman, T. Haufe, S. Sun, V. Jurisch, B. Kessler, R. Hinkel, R. Dirschinger, E. Martens, C. Jilek, A. Graf, S. Krebs, G. Santamaria, M. Kurome, V. Zakhartchenko, B. Campbell, K. Voelse, A. Wolf, T. Ziegler, S. Reichert, S. Lee, F. Flenkenthaler, T. Dorn, I. Jeremias, H. Blum, A. Dendorfer, A. Schnieke, S. Krause, M. C. Walter, N. Klymiuk, K. L. Laugwitz, E. Wolf, W. Wurst, C. Kupatt. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nature Medicine, 2020; DOI: 10.1038/s41591-019-0738-2
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.